Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bispebjerg Hospital
• Treatments: Glucagon-Like Peptide 1; Liraglutide

Criteria

Inclusion Criteria:

• Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.

• Age: 25-75 years

• BMI>25 kg/m2

• HbA1c 6,0-10 %

Exclusion Criteria:

• Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.

• Haemoglobin < 6.5 mmol/l

• Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.

• Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin

• Pregnancy

• Severe asthma

• Active cancer

• Severe co-morbidity with limited life-expectancy

• Estimated glomerular filtration rate (eGFR) <60 (measured at baseline)

• Severe hepatic co-morbidity

• Chronic alcohol abuse

• Heart failure with a left ventricular ejection fraction
• Atrial fibrillation

• Chronic or previous acute pancreatitis

• Inflammatory bowel disease.